Does nivolumab and ipilimumab provide a 5-year survival benefit for pleural mesothelioma?
For patients with unresectable pleural mesothelioma, the combination of nivolumab and ipilimumab (two immunotherapy drugs) has been studied as a first-line treatment. The 5-year follow-up from the CheckMate 743 trial shows that this combination improves long-term survival compared to standard chemotherapy. Specifically, 14% of patients on nivolumab plus ipilimumab were alive at 5 years versus 6% on chemotherapy 9. This benefit was seen regardless of tumor histology and was maintained even after accounting for patients who switched treatments.
What the research says
The CheckMate 743 trial is the key study providing 5-year data for nivolumab plus ipilimumab in pleural mesothelioma. With a median follow-up of 66.8 months, the overall survival benefit persisted: the hazard ratio was 0.74 (95% CI, 0.62 to 0.88) favoring the immunotherapy combination 9. Five-year survival rates were 14% for the immunotherapy group versus 6% for chemotherapy 9. The benefit was consistent across different tumor histologies 9. Exploratory biomarker analysis suggested that patients with low levels of monocytic myeloid-derived suppressor cells (M-MDSCs) may have greater benefit 9. No new safety concerns emerged with longer follow-up 9. Other sources discuss related topics but do not directly address this combination for pleural mesothelioma. For example, one study examined nivolumab plus chemotherapy in lung cancer 1, another looked at HITHOC in mesothelioma 2, and others focused on different cancers or treatments 345678. Therefore, the strongest evidence for 5-year survival benefit comes directly from the CheckMate 743 trial 9.
What to ask your doctor
- Is nivolumab plus ipilimumab a suitable first-line treatment option for my type of pleural mesothelioma?
- What are the potential side effects of this immunotherapy combination, and how are they managed?
- How does my tumor histology (epithelioid vs. non-epithelioid) affect the expected benefit?
- Should I have biomarker testing (such as M-MDSC levels) to help predict my response?
- What are the alternatives if I am not a candidate for immunotherapy?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.